Board of Directors
Marc Fishman, MD
Dr. Fishman founded Oncology Analytics in 2009. As a hematologist, oncologist and patient advocate, Dr. Fishman recognized that the rising costs and complexity of cancer treatment were compromising the ability for oncologists to make comprehensive, evidenced-based decisions for their patients’ treatment.
Dr. Fishman is board-certified in Internal Medicine and Hematology and developed his perspective on healthcare management and funding mechanisms through a wide variety of clinical experiences, including work in Kenya, New Zealand, Canada, Australia, and the United States. Dr. Fishman’s 20+ years of clinical treatment experience and exposure to multi-national health systems has reinforced his commitment to value-based care and a patient first approach, which measures the efficacy, toxicity and affordability of cancer treatment options, which put the patient in a position to achieve the best possible outcome.
Chief Executive Officer
Rick Dean serves as CEO of Oncology Analytics. Mr. Dean brings more than two decades of experience to Oncology Analytics, including successfully leading and growing innovative healthcare companies through various stages of maturation. Mr. Dean joined Oncology Analytics from Optum, the healthcare services arm of UnitedHealth Group. At Optum, Mr. Dean was a founding member of Optum Ventures, a venture capital fund focused on digital health innovation. Prior to Optum Ventures, he led global sales and growth for Optum Analytics.
Mr. Dean joined Optum after the acquisition of Humedica, a transformative population health and analytics company, where he was the company’s Chief Growth Officer. Prior to Humedica, Mr. Dean was Senior Vice President of North American sales for Sentillion, a highly successful venture-backed healthcare company that was acquired by Microsoft in 2010. Mr. Dean is a past board member of AMGA Analytics, the informatics subsidiary of the American Medical Group Association.
Mr. Dean earned a Bachelor of Science degree in finance from the University of North Carolina.
Co-Founder & Managing Partner, Oak HC/FT
Oak HC/FT Co-Founder & Managing Partner, Annie Lamont has more than 30 years of experience as a venture capitalist investing in transformative companies and entrepreneurs.
In 2014, Annie, along with Patricia Kemp and Andrew Adams, launched Oak HC/FT, a venture capital firm that invests in early to growth stage tech-enabled companies shaping the future of healthcare information and financial services. Before founding Oak HC/FT, Annie was a Managing Partner at Oak Investment Partners.
Annie is known as a leading healthcare and fintech investor, appearing on the Forbes Midas List, Institutional Investor’s FinTech Finance 40 list, and the Top 100 Venture Capitalist rankings published by CB Insights and The New York Times. She was the first recipient of the National Venture Capital Association’s award for Excellence in Healthcare Innovation. Annie was also honored with Healthcare Private Equity Association’s 2017 Russell L. Carson Award for lifetime achievement in healthcare investing.
She serves on the board of HCA, one of the world’s leading healthcare companies, and previously served on the Stanford Board of Trustees.
Annie received her bachelor’s degree in political science from Stanford University.
Thomas Hawes, M.D.
Tom Hawes is a member of the BlueCross BlueShield Fund Management team at Sandbox Industries and serves on the Sandbox Management Committee. He is the Board Chairman for Patientco, serves on the Board of Directors of Octave Bioscience, BehaveCare, and AbleTo and is a board observer of Phreesia, HeartFlow, and Healthify. Before joining Sandbox, Tom matched at Yale School of Medicine for residency and completed his first year of medical training at Greenwich Hospital. During his medical training, he worked on clinical studies at the ISK Institute for Orthopaedics and Sports Medicine and on outcomes research at the National Cancer Institute and NYMC’s Cardiothoracic Surgery Department. Tom holds a BA from Brigham Young University, an M.D. from New York Medical College and an MBA from Harvard Business School. He is also a Kauffman Fellow.
Michael Liang, Ph.D.
Michael Liang oversees healthcare investments on the venture side of Baird Capital and has been with the firm since 2006. Prior to joining Baird Capital, Mike was a healthcare investor with Advent Venture Partners (London, UK) and before that served in an operating role as a Director of R&D at Cortek, a spinal orthopedics company. Mike currently serves on the Board of Directors of Apervita, AiCure, GreenLight Biosciences, Oncology Analytics, and Zurex Pharma. He was previously a board member of Veniti (sold to Boston Scientific) Interlace Medical (sold to Hologic) and a board observer of TomoTherapy (NASDAQ: TOMO). Mike received a B.S. from the University of California Berkeley in bioorganic chemistry, completed a Ph.D. in biophysical chemistry from Stanford University, and conducted a postdoctoral fellowship at Harvard University.
Ezekiel J. “Zeke” Emanuel, M.D. Ph.D.
Venture Partner, Oak HC/FT
A Venture Partner since 2015, Zeke centers on growth equity and early-stage venture opportunities in healthcare information services.
He is the Vice Provost for Global Initiatives at the University of Pennsylvania, where he also is the Diane v.S. Levy and Robert M. Levy University Professor and Chair of the Department of Medical Ethics and Health Policy. In addition, he is a Senior Fellow at the Center for American Progress.
Previously, Zeke, who is a breast oncologist, was an associate professor at Harvard Medical School before joining the National Institutes of Health, where he was the founding chair of the Department of Bioethics. He also served as a Special Advisor on Health Policy to the Director of the Office of Management and Budget and National Economic Council.
He received a Bachelor of Science degree in chemistry from Amherst College, a Master of Science degree in biochemistry from Oxford University, a Doctor of Medicine degree from Harvard Medical School and a Ph.D. in political philosophy from Harvard University.
Zeke is the author of several books, including Reinventing American Health Care: How the Affordable Care Act will Improve our Terribly Complex, Blatantly Unjust, Outrageously Expensive, Grossly Inefficient, Error Prone System and Brothers Emanuel: A Memoir of an American Family. He is an op-ed contributor to The New York Times, The Wall Street Journal, Forbes and Fortune and a regular contributor to MSNBC, Fox News and CNN.
He is a member of the Council on Foreign Relations and the chair of the meta-council on the Future of Health Care Committee for the World Economic Forum. He has received numerous awards, including election to the Institute of Medicine of the National Academy of Science, the Association of American Physicians and the Royal College of Medicine. Among other awards, Hippocrates Magazine selected him as Doctor of the Year in Ethics. He is a member of the board of VillageMD.
Co-Founder & Managing Partner of Ardan Equity Partners
Michael Weintraub is Co-Founder and Managing Partner of Ardan Equity Partners, a healthcare enterprise software private equity firm. Weintraub is Founding Chairman of Phreesia (NYSE: PHR), the leading patient intake company. Previously, Michael was Co-Founder and Managing Partner of Optum Ventures, focused on digital health innovation. Weintraub was Co-Founder and CEO of Humedica, a pioneer and leader in the the field of population health management and big data. Following Humedica’s acquisition by UnitedHealth Group (UHG), Michael broadened his role within UHG as President and CEO of Optum Analytics. Prior to launching Humedica, Weintraub was a Senior Managing Director at Leerink Partners (now SVB Leerink), a leading healthcare investment bank. Michael also was CEO of PharMetrics, a health care informatics company, which was acquired by IMS Health (now IQVIA). Weintraub currently serves as Chairman of BroadReach Healthcare, a global healthcare company based in Cape Town, South Africa. Michael serves as Chairman of Holmusk, a Behavioral Health Real World Evidence company. Weintraub is a member of the board of directors of Corrona, Oncology Analytics, NewFire Partners, and The College Diabetes Network (CDN). Michael also focuses on healthcare innovation as an Entrepreneur in Residence at Harvard Business School, and an Advisory Board member of the Innovation and Digital Health Accelerator at Boston Children’s Hospital. Weintraub received his Bachelor’s Degree in Economics from Brandeis University and an MBA from Harvard Business School.
Peter B. Bach, M.D., MAPP
Director, Memorial Sloan Kettering’s Center for Health Policy and Outcomes
Dr. Bach is a physician, epidemiologist, researcher, and respected healthcare policy expert whose work focuses on the cost and value of anticancer drugs. Dr. Bach is leading efforts to increase understanding of the US drug development process and develop new models for drug pricing that include value to patients.
Dr. Bach has published more than 100 peer-reviewed articles and editorials in scientific journals such as the New England Journal of Medicine and the Journal of the American Medical Association. He has also written numerous healthcare-related op-eds and been featured in mainstream media outlets such as the New York Times, New York magazine, the Wall Street Journal, Forbes, NPR, and 60 Minutes.